HPB - British Journal of Surgery

Surgical oncology

Scientific Surgery

Laparoscopic versus open resection for colorectal liver metastases: The OSLO-COMET Randomized Controlled Trial. Ann Surg 2018; 267: 199-207.

Authors: Fretland ÅA, Dagenborg VJ, Bjørnelv GMW, Kazaryan AM, Kristiansen R, Fagerland MW et al.

Scientific Surgery

Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst 2017; 109. doi: 10.1093/jnci/djx015.

Authors: Ruers T, Van Coevorden F, Punt CJA, Pierie J-PEN, Borel-Rinkes I, Ledermann JA et al.

Scientific Surgery

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017; 389: 1011–24.

Authors: Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM et al.

Scientific Surgery

Randomized controlled trial of pancreaticojejunostomy versus stapler closure of the pancreatic stump during distal pancreatectomy to reduce pancreatic fistula. Ann Surg 2016; 264: 180-187.

Authors: Kawai M, Hirono S, Okada K, Sho M, Nakajima Y, Eguchi H et al.

Scientific Surgery

Duct-to-mucosa vs invagination for pancreaticojejunostomy after pancreaticoduodenectomy: a prospective, randomized controlled trial from a single surgeon. J Am Coll Surg 2016; 222: 10-18.

Authors: Bai X, Zhang Q, Gao S, Lou J, Li G, Zhang Y et al.

Scientific Surgery

Pancreatogastrostomy versus pancreatojejunostomy for RECOnstruction after PANcreatoduodenectomy (RECOPANC, DRKS 00000767): perioperative and long-term results of a multicentre randomized controlled trial. Ann Surg 2016; 263: 440-449.

Authors: Keck T, Wellner UF, Bahra M, Klein F, Sick O, Niedergethmann M et al.

Scientific Surgery

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 2016; 388: 248–25716.

Authors: Uesaka K, Boku N, Kukutomi A, Okamura Y, Knoishi M, Matsumoto I et al.

Scientific Surgery

Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). Cancer 2016; 122: 574-581.

Authors: Leone F, Marino D, Cereda S, Filippi R, Belli C, Spadi R et al.